LV10962B - New peptides - Google Patents

New peptides Download PDF

Info

Publication number
LV10962B
LV10962B LVP-95-197A LV950197A LV10962B LV 10962 B LV10962 B LV 10962B LV 950197 A LV950197 A LV 950197A LV 10962 B LV10962 B LV 10962B
Authority
LV
Latvia
Prior art keywords
phe
tic
tyr
boc
peptide
Prior art date
Application number
LVP-95-197A
Other languages
English (en)
Latvian (lv)
Other versions
LV10962A (lv
Inventor
Peter Schiller
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of LV10962A publication Critical patent/LV10962A/xx
Publication of LV10962B publication Critical patent/LV10962B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/70Enkephalins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LVP-95-197A 1993-01-05 1995-06-29 New peptides LV10962B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9300012A SE9300012D0 (sv) 1993-01-05 1993-01-05 New peptides
PCT/SE1993/001090 WO1994015959A1 (en) 1993-01-05 1993-12-20 New peptides

Publications (2)

Publication Number Publication Date
LV10962A LV10962A (lv) 1995-12-20
LV10962B true LV10962B (en) 1997-04-20

Family

ID=20388466

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-95-197A LV10962B (en) 1993-01-05 1995-06-29 New peptides

Country Status (25)

Country Link
US (1) US5602099A (hu)
EP (1) EP0678099A1 (hu)
JP (1) JPH08505386A (hu)
KR (1) KR960700269A (hu)
CN (1) CN1096515A (hu)
AP (1) AP508A (hu)
AU (1) AU681372B2 (hu)
CA (1) CA2152380A1 (hu)
CZ (1) CZ171195A3 (hu)
EE (1) EE9400326A (hu)
FI (1) FI953302A (hu)
HU (1) HUT72597A (hu)
IL (1) IL108169A0 (hu)
IS (1) IS4115A (hu)
LV (1) LV10962B (hu)
MX (1) MX9400255A (hu)
NO (1) NO952650L (hu)
NZ (1) NZ259597A (hu)
PL (1) PL309778A1 (hu)
SE (1) SE9300012D0 (hu)
SI (1) SI9400005A (hu)
SK (1) SK83995A3 (hu)
WO (1) WO1994015959A1 (hu)
YU (1) YU394A (hu)
ZA (1) ZA9455B (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221092B1 (en) * 1993-12-23 2002-08-28 Novo Nordisk As Compounds with growth hormone releasing properties
IS4261A (is) * 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
IL114046A0 (en) * 1994-06-20 1995-10-31 Astra Ab New opioid peptide antagonists
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
RU2067000C1 (ru) * 1994-06-29 1996-09-27 Владислав Исакович Дейгин Пептид и способ его получения
SE9402880D0 (sv) * 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
EP0837857A4 (en) * 1995-03-29 1998-08-05 Merck & Co Inc FARNESYL-PROTEIN TRANSFERASE INHIBITORS
CA2216532A1 (en) * 1995-03-29 1996-10-31 S. Jane Desolms Inhibitors of farnesyl-protein transferase
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6306576B1 (en) * 1999-02-19 2001-10-23 Cleveland Clinic Foundation Diagnostic methods for asthma
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
WO2015200828A1 (en) * 2014-06-27 2015-12-30 H. Lee Moffit Cancer Center And Research Institute, Inc. Conjugates for immunotherapy

Also Published As

Publication number Publication date
NZ259597A (en) 1996-07-26
PL309778A1 (en) 1995-11-13
IL108169A0 (en) 1994-04-12
FI953302A0 (fi) 1995-07-04
LV10962A (lv) 1995-12-20
KR960700269A (ko) 1996-01-19
AU5844894A (en) 1994-08-15
AP9400605A0 (en) 1994-01-31
WO1994015959A1 (en) 1994-07-21
CN1096515A (zh) 1994-12-21
SK83995A3 (en) 1996-09-04
CZ171195A3 (en) 1996-09-11
CA2152380A1 (en) 1994-07-21
YU394A (sh) 1997-07-31
ZA9455B (en) 1994-07-05
EE9400326A (et) 1996-04-15
NO952650L (no) 1995-08-30
HUT72597A (en) 1996-05-28
AP508A (en) 1996-07-22
SI9400005A (en) 1994-12-31
SE9300012D0 (sv) 1993-01-05
US5602099A (en) 1997-02-11
AU681372B2 (en) 1997-08-28
NO952650D0 (no) 1995-07-04
FI953302A (fi) 1995-07-04
MX9400255A (es) 1994-07-29
JPH08505386A (ja) 1996-06-11
HU9502041D0 (en) 1995-09-28
IS4115A (is) 1994-07-06
EP0678099A1 (en) 1995-10-25

Similar Documents

Publication Publication Date Title
LV10962B (en) New peptides
EP1163263B1 (en) Dalda analogs and their use
US5455230A (en) Delta opioid receptor antagonists and their use as analgesic agents
US5811400A (en) Peptide derivatives with δ opioid receptor antagonist or mixed μ agδ antagonist effects
Misicka et al. Topographical requirements for delta opioid ligands: presence of a carboxyl group in position 4 is not critical for deltorphin high delta receptor affinity and analgesic activity
JP2633369B2 (ja) ペプチド
US5733881A (en) Opioid peptide antagonists
US5786447A (en) Opioid peptide analogs
AU691630C (en) New opioid peptide antagonists
EP0777682A1 (en) New opioid peptide antagonists